Tag Archives: Pfizer

  1. Pfizer Clinical Trial Update

    Posted on December 8, 20164:33 pm

      CureDuchenne is pleased to share the following updates from Pfizer pertaining to the on-going multicenter Phase II clinical trial of the investigational compound, domagrozumab (PF-06252616) in boys with Duchenne muscular dystrophy (DMD). Domagrozumab is an experimental, infused, anti-myostatin monoclonal antibody.  Myostatin is a naturally occurring protein in muscles that helps control muscle growth; it Read more »

  2. Learn. Engage. Empower.

    Posted on October 10, 20169:15 pm

      Caring for a child with Duchenne can be daunting, complicated, and often times, isolating. But it doesn’t have to be. On October 22, CureDuchenne Cares will hold its inaugural Family Summit bringing together Duchenne families, medical providers and researchers for a daylong event focused on education and fellowship. The goal of this summit is Read more »

  3. Pfizer, Bamboo and CureDuchenne – An Endorsement on the Right Track

    Posted on August 1, 20167:24 pm

      Today, we are very pleased to announce that Pfizer has acquired Bamboo Therapeutics, a gene therapy company we invested in earlier this year through CureDuchenne Ventures. The deal is valued at up to $645 million. Bamboo, led by Dr. Richard Jude Samulski, PhD, the Director of the Gene Therapy Center at UNC, and Dr. Xiao Read more »

  4. Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy

    Posted on December 17, 20146:24 pm

    Pfizer Inc. (NYSE:PFE) announced today enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. PF-06252616 is an experimental, infused, anti-myostatin monoclonal antibody. Myostatin is a naturally occurring protein in muscles Read more »